VIDEO: Study shows antibody-drug conjugate efficacy against HER2-low, HER2-ultralow tumors
SAN ANTONIO — In this video, Patrick McIntire, MD, discusses findings from the DESTINY-Breast04 and DESTINY-Breast06 trials presented at San Antonio Breast Cancer Symposium.
The study assessed the rates of hormone receptor-positive, HER2-low, HER2-ultralow and HER2-null tumors in patients with metastatic breast cancer to characterize patient eligibility for HER2-directed antibody-drug conjugates.
“[It] appears that these [antibody-drug conjugates] have what they call ‘bystander effect,’ which, in clinical terms, means that not only are they efficacious on the cell that they target but they may be efficacious on the adjacent cells,” McIntire, subspecialty director for breast pathology at Cleveland Clinic, said.
“The purpose of our study was to look at a year’s-worth of metastatic tumors and look at essentially what proportion of these tumors may be eligible for the [antibody-drug conjugates] that, otherwise, they traditionally would not [be eligible for],” McIntire added.
Reference:
- Hoda R, et al. Abstract P1-07-10. Presented at: San Antonio Breast Cancer Symposium; Dec. 10-13, 2024; San Antonio.
Collapse
Healio Interviews